You have not verified your Email yet. Please verify your Email to create alerts
Verify Email
BETA
|
Beta Drugs
|
Zenotech Laboratorie
|
Cipla
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.02 % | 10.34 % | 11.43 % |
|
5yr average Equity Multiplier
|
1.82 | 1.38 | 1.39 |
|
5yr Average Asset Turnover Ratio
|
0.97 | 0.31 | 0.76 |
|
5yr Avg Net Profit Margin
|
11.94 % | -13.36 % | 10.96 % |
|
Price to Book
|
0.0 | 4.66 | 4.38 |
|
P/E
|
43.19 | 35.65 | 29.34 |
|
5yr Avg Cash Conversion Cycle
|
4.72 Days | 31.2 Days | -3.69 Days |
|
Inventory Days
|
40.73 Days | 145.01 Days | 59.85 Days |
|
Days Receivable
|
86.71 Days | 61.38 Days | 44.13 Days |
|
Days Payable
|
110.62 Days | 477.06 Days | 114.64 Days |
|
5yr Average Interest Coverage Ratio
|
11.36 | -4.03 | 23.71 |
|
5yr Avg ROCE
|
25.44 % | 7.48 % | 15.24 % |
|
5yr Avg Operating Profit Margin
|
21.55 % | 11.69 % | 22.51 % |
|
5 yr average Debt to Equity
|
0.31 | 0.2 | 0.13 |
|
5yr CAGR Net Profit
|
30.75 % | n/a | 12.9 % |
|
5yr Average Return on Assets
|
11.68 % | 7.92 % | 8.36 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 68.84 % | 33.47 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.05 % | 0.0 | -3.23 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 1.08 % |
|
Beta Drugs
|
Zenotech Laboratorie
|
Cipla
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|
